MarketCap
Facebook
X
Telegram
Celldex Therapeutics Income Statement 2025-2008 | CLDX
Brief overview of revenue and earnings at Celldex Therapeutics
The conclusions below are based on five years of reported results. Revenue at Celldex Therapeutics moved from $7.4 million in 2020 to $1.5 million in 2025. Overall revenue changed by −79.2%, equal to an annualized rate of about −26.9%. The negative rate indicates weakening core operations.
Gross profit changed from $7.2 million to $1.3 million (−81.4%). The cost base moved against the top-line trend and weighed on the gross result. Comparing the endpoints gives gross margins of 97.3% and 87.1%. The margin decline reflects a less favorable sales-and-cost structure.
The five-year EBITDA result moved by −377.9%: from −59.4 million dollars to −284 million dollars. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −801.1% at the start and −18381% at the end. A lower EBITDA share weakens the quality of the result.
The final result was −59.8 million dollars initially and −259 million dollars in the final year. The negative result deepened, showing weaker final efficiency.
Over the period, capitalization shifted from 641 thousand dollars to 2 billion dollars (+318112.3%). Capitalization rose despite deteriorating fundamentals.
Conclusion
The current trajectory does not yet confirm a sustainable recovery. Caution is warranted because of pressure on operating profitability, limited operating profitability and lower net income. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.04 B | 1.31 B | 2.33 B | 2 M | 1.33 M | 641 K | 33.5 M | 64.2 M | 360 M | 330 M | 806 M | 1.91 B | 2.11 B | 420 M | 177 M | 3.03 B | 3.34 B | - |
Shares |
66.4 M | 64.4 M | 48.4 M | 46.9 K | 42.9 K | 29.6 K | 14.5 M | 10.4 M | 8.57 M | 6.77 M | 6.47 M | 5.96 M | 5.32 M | 3.85 M | 2.63 M | 31.9 M | 19.8 M | - |
Historical Prices |
30.7 | 20.4 | 48 | 42.7 | 31 | 21.6 | 2.32 | 7.65 | 41.4 | 48.9 | 124 | 321 | 387 | 112 | 71.1 | 94.9 | 168 | 270 |
Net Income |
-259 M | -158 M | -141 M | -112 M | -70.5 M | -59.8 M | -50.9 M | -151 M | -93 M | -129 M | -127 M | -118 M | -81.6 M | -59.1 M | -44.8 M | -2.53 M | -36.5 M | - |
Revenue |
1.54 M | 7.02 M | 6.88 M | 2.36 M | 4.65 M | 7.42 M | 3.57 M | 9.54 M | 12.7 M | 6.79 M | 5.48 M | 3.59 M | 4.11 M | 11.2 M | 9.26 M | 46.8 M | 15.2 M | - |
Cost of Revenue |
200 K | 200 K | 300 K | 100 K | 100 K | 200 K | 100 K | 700 K | 700 K | 1.6 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 5.48 M | 3.59 M | 1.78 M | 427 K | 146 K | - | - | - |
Operating Income |
-287 M | -195 M | -155 M | -115 M | -71.2 M | -63.4 M | -55 M | -156 M | -122 M | -133 M | -130 M | -122 M | -81.4 M | -58.1 M | -43.4 M | -6.46 M | -36.8 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | 927 K | 1.58 M | 1.8 M | 1.34 M | 452 K | - |
EBITDA |
-284 M | -192 M | -152 M | -112 M | -68.2 M | -59.4 M | -49.7 M | -76.2 M | -108 M | -132 M | -129 M | -121 M | -80.4 M | -57 M | -41.5 M | -3.74 M | -34.3 M | - |
Operating Expenses |
- | - | - | - | - | - | 58.1 M | 85.9 M | 122 M | 140 M | 135 M | 126 M | 83.2 M | 58.5 M | 43.6 M | - | - | - |
General and Administrative Expenses |
43.8 M | 38.5 M | 30.9 M | 27.2 M | 20.5 M | 14.5 M | 15.4 M | 19.3 M | 25 M | 36 M | 33.8 M | 20.6 M | 14.8 M | 10 M | - | 10.4 M | 17.1 M | - |
All numbers in USD currency
Quarterly Income Statement Celldex Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
77.8 M | 66.6 M | 66.4 K | 66.4 K | 66.4 K | 66.4 M | 66.3 K | 66 K | 58.9 K | 55.9 M | 47.3 K | 47.3 K | 47.2 K | 47.2 M | 46.9 K | 46.8 K | 46.7 K | 46.7 M | 45.5 M | 39.6 M | 39.6 M | 39.6 M | 39.3 M | 22.1 M | 17.4 M | 17 M | 15.3 M | 14 M | 12.3 M | 12 M | 10.9 M | 9.83 M | 9.37 M | 9.23 M | 130 M | 125 M | 123 M | 121 M | 101 M | 98.8 M | 98.7 M | 98.7 M | 98.6 M | 98.5 M | 92.4 M | 89.6 M | 89.4 M | 89.4 M | 89.3 M | 89.2 M | 81 M | 80.9 M | 74 M | 64.4 M | 59.5 M | 58.7 M | 50.1 M | 44.2 M | 44.1 M | 37.5 M | 32 M |
Net Income |
-73.5 M | -78.7 M | -67 M | -56.6 M | -53.8 M | - | -42.1 M | -35.8 M | -32.8 M | - | -38.3 M | -30.5 M | -29.4 M | - | -26.8 M | -36 M | -23 M | - | -20.5 M | -13.4 M | -16.5 M | -21.9 M | -14.2 M | -11 M | -12.6 M | -10.4 M | -11.4 M | -11.8 M | -17.2 M | -9.4 M | -7.24 M | -16.4 M | -118 M | -3.84 M | -26.4 M | -28.6 M | -34.3 M | -32.3 M | -29.6 M | -32 M | -34.7 M | -32.7 M | -32 M | -32.4 M | -30.2 M | -31.8 M | -28.1 M | -28.3 M | -29.9 M | -22.1 M | -23.1 M | -19 M | -17.3 M | -16.8 M | -15 M | -13.8 M | -13.5 M | -12.7 M | -11.8 M | -10.2 M | -10.1 M |
Revenue |
22 K | 15 K | - | 730 K | 695 K | - | 3.19 M | 2.5 M | 156 K | - | 1.52 M | 268 K | 967 K | - | 407 K | 163 K | 174 K | - | 153 K | 3.48 M | 685 K | 3.79 M | 668 K | 236 K | 2.73 M | 887 K | 546 K | 715 K | 1.42 M | 1.76 M | 941 K | 2.76 M | 4.07 M | 3.46 M | 3.92 M | 3.83 M | 1.53 M | 1.87 M | 2.22 M | 1.39 M | 1.3 M | 1.79 M | 1.03 M | 2.18 M | 486 K | 1.48 M | 1.1 M | 592 K | 416 K | 620 K | 980 K | 97 K | 2.41 M | 3.65 M | 3.11 M | 2.01 M | 2.43 M | 2.43 M | 2.36 M | 1.95 M | 2.52 M |
Operating Income |
-80.6 M | -84.4 M | -73.6 M | -63.9 M | -62.7 M | - | -52.1 M | -46.3 M | -40.6 M | - | -41.2 M | -33.2 M | -32.5 M | - | -27.7 M | -36.4 M | -23.3 M | - | -20.8 M | -13.4 M | -16.6 M | - | -14.3 M | -11.4 M | -12.9 M | - | -11.8 M | -12.3 M | -17.9 M | - | -7.76 M | -16.9 M | -120 M | - | -32 M | -28.9 M | -35.1 M | - | -30 M | -32.4 M | -35.7 M | - | -32.4 M | -32.8 M | -31 M | - | -30.3 M | -28.5 M | -31.5 M | - | -23.3 M | -18.7 M | -17.4 M | - | -14.8 M | -13.5 M | -13.3 M | - | -11.5 M | -9.88 M | -9.66 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 K | 519 K | 310 K | - | 381 K | 411 K | 433 K | - | 438 K | 434 K | 485 K |
EBITDA |
-78.9 M | -83.6 M | - | - | -61.9 M | - | - | - | -39.8 M | - | - | - | -31.7 M | - | -25.5 M | -34.8 M | -22.4 M | - | -18.5 M | -11.9 M | -15.9 M | - | -11.2 M | -9.05 M | -11.7 M | - | -8.13 M | -9.75 M | -16.6 M | - | -4.91 M | -16.9 M | -119 M | - | -28.6 M | -26.6 M | -33.7 M | - | -27.9 M | -30.9 M | -35 M | - | -30.2 M | -31.4 M | -30.3 M | - | -28.6 M | -27.4 M | -30.9 M | - | -21.8 M | -17.7 M | -16.9 M | - | -13.2 M | -12.4 M | -12.7 M | - | -9.78 M | -8.75 M | -9.1 M |
General and Administrative Expenses |
13.1 M | 11.4 M | 10.7 M | 10.4 M | 10.8 M | - | 10.1 M | 9.13 M | 9.1 M | - | 8.22 M | 7.22 M | 6.64 M | - | 6.53 M | 7.15 M | 6.91 M | - | 5.82 M | 4.31 M | 4.12 M | - | 3.64 M | 3.53 M | 3.67 M | - | 3.4 M | 3.91 M | 4.9 M | - | 3.72 M | 5.62 M | 5.59 M | - | 5.35 M | 6.53 M | 7.23 M | - | 6.95 M | 7.79 M | 9.31 M | - | 8.49 M | 8.18 M | 6.09 M | - | 5 M | 4.79 M | 4.58 M | - | 3.58 M | 3.41 M | 3.14 M | - | 2.84 M | 2.22 M | 2.32 M | - | 2.27 M | 2.24 M | 2.34 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Celldex Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
